PRMT2 (Gene)

Synonyms:ENTREZ:3275, HGNC:5186, HRMT1L1, MIM:601961, NM_001242864, NM_001242865, NM_001242866, NM_001286676, NM_001286677, NM_001286678, NM_001535, NM_206962, NP_001229793, NP_001229794, NP_001229795, NP_001273605, NP_001273606, NP_001273607, NP_001526, NP_996845, PRMT2, XM_005261111, XM_006723998, XM_006723999, XM_006724000, XM_017028339, XM_017028340, XP_005261168, XP_006724061, XP_006724062, XP_006724063, XP_016883828, XP_016883829, XR_001754841, protein arginine methyltransferase 2
Id:ENSG00000160310
Entrez:3275
Description:protein arginine methyltransferase 2
Enables several functions, including nuclear receptor binding activity; peroxisome proliferator activated receptor binding activity; and protein homodimerization activity. Involved in several processes, including histone methylation; regulation of androgen receptor signaling pathway; and regulation of transcription, DNA-templated. Located in cytosol and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View PRMT2's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with PRMT2.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using PRMT2.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for PRMT2.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with PRMT2.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.